Informations générales (source: ClinicalTrials.gov)

NCT02596191 En recrutement
Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers (CMT-TOOLS)
Interventional
  • Maladie de Charcot-Marie-Tooth
  • Maladie
  • Syndromes de compression nerveuse
  • Maladies des dents
  • Neuropathie héréditaire motrice et sensitive
N/A
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
juin 2016
décembre 2027
29 juin 2024
This is a 2-year follow-up study of a cohort of 60 CMT1A patients. The objective is to identify markers allowing to better understand the phenotypic variability observed on patients with CMT1A, to identify predictive markers of the disease's progression and to provide validated measurement tools that can be used as outcome measures in future clinical trials.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Assistance Publique Hôpitaux de Marseille - 13010 - Marseille - France Shahram Attarian, MD En recrutement Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CHU Gui de Chauliac, CHU MONTPELLIER - 34285 - Montpellier - France William Camu En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Patients with CMT 1A disease

- Diagnosis of CMT 1A confirmed by genotyping (duplication of the 17p11.2 region)


- Patients suffering from co-morbidity at the origin of peripheral neuropathy
(diabetes, hypothyroidism, renal insufficiency, drugs...) or muscle, articular,
rheumatological disease

- With HIV or cancer

- With a significant progressive disease in the previous month

- With a contra-indication for MRI

- With a dislocation, fracture, or recent surgery (less than 6 months before
inclusion)

- with alcohol or psychoactive substances abuse

- Treated by an anti-inflammatory drug over the past four weeks

- Pregnant or breastfeeding women

- Homeless patients